PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

In this video roundtable, watch 3 experts give their perspectives on the optimal management of patients with pancreatic cancer using PARP inhibitors, as well as emerging strategies with PARP inhibitors that they find promising.

Dirk Arnold, MD, PhD Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: December 14, 2021 Expired: December 13, 2022

Assessing Mutations in Homologous Recombination Repair Genes: BRCA1/2 and Other Alterations

Personalizing First-line Chemotherapy and Maintenance PARP Inhibition Therapy Decisions

Clinical Pearls for Managing Patients on PARP Inhibitor Therapy

Future Directions for PARP Inhibition in Pancreatic Cancer

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.

Dirk Arnold, MD, PhD Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Released: December 14, 2021